Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

BACKGROUND: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes and obesity. They elicit robust improvements in glycemic control and weight loss, combined with cardioprotection in individuals at risk of or with pre-existing cardiovascular disease. These attribute...

Descripción completa

Detalles Bibliográficos
Autores principales: Baggio, Laurie L., Drucker, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085566/
https://www.ncbi.nlm.nih.gov/pubmed/32987188
http://dx.doi.org/10.1016/j.molmet.2020.101090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085566/
https://www.ncbi.nlm.nih.gov/pubmed/32987188
http://dx.doi.org/10.1016/j.molmet.2020.101090

Ejemplares similares